Immune Effect of Dexmedetomidine in Patients Undergoing to Spinal Fusion

• Status: Unknown status
• Trial end date: 2017-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Alpha-agonist in anesthesia display immunomodulatory effect in addition to antiadrenergic control. This effect of the immune system can be a key to a better perioperative safety and quality.

The association of dexmedetomidine at general anesthesia adds up organic protection and inflammatory control to a surgery trauma owing to antinociception and immunomodulatory effect.

The aim this study is evaluate if the association of dexmedetomidine at general anesthesia standing effective immunomodulatory control to trauma and improve changes at outcomes in patients undergoing to spinal fusion.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sarah Network of Rehabilitation Hospitals
• Collaborator: University of Brasilia
• Treatments: Anesthetics; Dexmedetomidine

Criteria

Inclusion Criteria:

• ASA I-III;

• Age > 18;

• Elective surgery to spinal fusion, and;

• Informed consent signed.

Exclusion Criteria:

• Patients with severe heart disease with New York Heart Association class > III;

• Severe arrhythmia;

• Uncontrolled hypertension or hypotension;

• Hemodynamic unstably;

• Hypersensitivity with drugs;

• Cognitive deficiency, dementia, or delirium;

• Weight up to 100 kg and/or body mass index (BMI) greater than or equal to 40;

• Illicit drugs users and/or alcoholic;

• Steroids and/or non-steroids anti-inflammatory chronic users;

• Tricyclic antidepressants users;

• Hepatic or renal compromised and;

• Infective disease.